Prognostic factors for patients treated with abiraterone

AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvim, Cecília M, Mansinho, André, Paiva, Rita S, Brás, Raquel, Semedo, Patrícia M, Lobo-Martins, Soraia, da Ponte, Carolina B, Macedo, Daniela, Ribeiro, Leonor, dos Reis, José P, Fernandes, Isabel, Costa, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997918/
https://www.ncbi.nlm.nih.gov/pubmed/32025327
http://dx.doi.org/10.2144/fsoa-2019-0079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997918/
https://www.ncbi.nlm.nih.gov/pubmed/32025327
http://dx.doi.org/10.2144/fsoa-2019-0079

Ejemplares similares